Okihiro syndrome due to 20q13 microdeletion

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:261638OMIM:607323Q87.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Okihiro syndrome due to 20q13 microdeletion is a rare genetic condition caused by a chromosomal microdeletion on the long arm of chromosome 20 (20q13) that encompasses the SALL4 gene. This condition is a specific genetic subtype of Okihiro syndrome, also known as Duane-radial ray syndrome (DRRS) or acro-renal-ocular syndrome. It is characterized by the combination of Duane anomaly (a congenital eye movement disorder affecting the ability to move the eye outward, and sometimes inward, due to abnormal innervation of the eye muscles) and upper limb malformations, particularly radial ray defects. Radial ray abnormalities can range from mild thumb hypoplasia or triphalangeal thumbs to complete absence of the thumb or radius. The syndrome can affect multiple body systems beyond the eyes and limbs. Patients may present with renal anomalies (such as kidney malformations or ectopic kidneys), hearing loss (sensorineural or conductive), cardiac defects, and anorectal malformations. The severity and combination of features can vary considerably, even among affected members of the same family. Some individuals may have subtle findings, while others can be more significantly affected. Because this form is caused by a microdeletion rather than a point mutation in SALL4, affected individuals may occasionally exhibit additional features related to the loss of neighboring genes (contiguous gene deletion syndrome). Management is multidisciplinary and symptom-based, involving orthopedic surgery for limb anomalies, ophthalmologic monitoring for Duane anomaly, audiologic evaluation, cardiac assessment, and renal imaging. There is currently no cure or disease-specific therapy; treatment focuses on surgical correction and supportive care tailored to each patient's clinical presentation. Genetic counseling is recommended for affected families.

Also known as:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Okihiro syndrome due to 20q13 microdeletion.

View clinical trials →

No actively recruiting trials found for Okihiro syndrome due to 20q13 microdeletion at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Okihiro syndrome due to 20q13 microdeletion community →

No specialists are currently listed for Okihiro syndrome due to 20q13 microdeletion.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Okihiro syndrome due to 20q13 microdeletion.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Okihiro syndrome due to 20q13 microdeletionForum →

No community posts yet. Be the first to share your experience with Okihiro syndrome due to 20q13 microdeletion.

Start the conversation →

Latest news about Okihiro syndrome due to 20q13 microdeletion

No recent news articles for Okihiro syndrome due to 20q13 microdeletion.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Okihiro syndrome due to 20q13 microdeletion

What is Okihiro syndrome due to 20q13 microdeletion?

Okihiro syndrome due to 20q13 microdeletion is a rare genetic condition caused by a chromosomal microdeletion on the long arm of chromosome 20 (20q13) that encompasses the SALL4 gene. This condition is a specific genetic subtype of Okihiro syndrome, also known as Duane-radial ray syndrome (DRRS) or acro-renal-ocular syndrome. It is characterized by the combination of Duane anomaly (a congenital eye movement disorder affecting the ability to move the eye outward, and sometimes inward, due to abnormal innervation of the eye muscles) and upper limb malformations, particularly radial ray defects.

How is Okihiro syndrome due to 20q13 microdeletion inherited?

Okihiro syndrome due to 20q13 microdeletion follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Okihiro syndrome due to 20q13 microdeletion typically begin?

Typical onset of Okihiro syndrome due to 20q13 microdeletion is neonatal. Age of onset can vary across affected individuals.